Factoring the "What Ifs" into Supply Forecasting:

Why Building a Durable Supply Chain Around a Protocol is Critical

Today, only 12% of investigational drugs win marketing approval in the United States.

The pressure is on to deliver new products faster and more efficiently, and this herculean task doesn't come without difficulties.

Some challenges include (but are certainly not limited to):

  • Growth of Clinical Trials: The competition is fierce. In 2018, there were 277,000+ trials registered at ClinicalTrials.gov
  • Patient Recruitment Challenges: 80% of pharma clinical trials do not meet enrollment deadlines, this can result in an average loss of 1.3 million per day per drug candidate.
  • Shorter Study Start-Up Timelines: Shorter timelines = shorter study lead times. How can you adhere to the narrower time window, while making sure you're leaving little room for error?

Download this whitepaper and discover additional challenges as well as aspects to consider when developing a supply plan, the influence of early decisions and impact on outcome as a trial progresses, and how decisions can put patients and the trial at risk.



Field will not be visible to web visitor

Copyright 2019 Industry Dive